Can a nationwide registry unlock the secrets of adult spinal muscular atrophy?
NCT ID NCT05618379
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This study is a nationwide registry in China that will follow adults with a genetic form of spinal muscular atrophy (SMA). The goal is to describe how the disease naturally progresses over time and how disease-modifying treatments are used in real-world settings. By collecting data from 200 participants, researchers hope to gain a clearer picture of the condition in adults, which may help improve future care and treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- This registry could help doctors better understand how spinal muscular atrophy progresses in adults and how treatments are used in real life, potentially leading to improved care and support strategies.
- What could go wrong
- As an observational registry, it does not test a new treatment, so it won't directly lead to a cure. The findings may also be specific to the Chinese population and may not apply to other regions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCULAR ATROPHY, SPINAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
Peking University Shenzhen Hospital
Shenzhen, Guangdong, 518000, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, 250012, China
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350005, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
-
The First People's Hospital of Yunnan Province
Kunming, Yun'nan, 650032, China
-
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Xiangya Hospital of Central South University
Changsha, Hunan, 410008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a spinal injection safely slow spinal muscular atrophy? a real-world study in korea seeks answers.
- New drug BIIB115 aims to build on gene therapy for spinal muscular atrophy
- New hope for SMA babies: boosting gene therapy with a Follow-Up drug
- Real-World data reveals treatment patterns for kids with SMA
- Massive data dive reveals how SMA drugs perform outside the lab
- Higher doses of SMA drug tested for Long-Term safety